| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mei Han, Xiang Yang Zhang, Da Chun Chen, Yun Long Tan, Chong Sheng Song, Ying Hua Yu, Xu Feng Huan. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics. International clinical psychopharmacology. vol 30. issue 2. 2015-11-06. PMID:25568968. |
cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics. |
2015-11-06 |
2023-08-13 |
Not clear |
| Mei Han, Xiang Yang Zhang, Da Chun Chen, Yun Long Tan, Chong Sheng Song, Ying Hua Yu, Xu Feng Huan. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics. International clinical psychopharmacology. vol 30. issue 2. 2015-11-06. PMID:25568968. |
cognitive function was assessed in 418 patients with schizophrenia on long-term treatment with apds (215 on clozapine, 91 on risperidone and 112 on typical apds) and 159 healthy controls using the repeatable battery for the assessment of neuropsychological status (rbans). |
2015-11-06 |
2023-08-13 |
Not clear |
| Thomas E Winkler, Hadar Ben-Yoav, Sheryl E Chocron, Eunkyoung Kim, Deanna L Kelly, Gregory F Payne, Reza Ghodss. Electrochemical study of the catechol-modified chitosan system for clozapine treatment monitoring. Langmuir : the ACS journal of surfaces and colloids. vol 30. issue 48. 2015-10-26. PMID:25383917. |
such point-of-care monitoring will allow for broader use of clozapine by increasing convenience to patients as well as medical professionals, thus improving the lives of people affected by schizophrenia through personalized medicine. |
2015-10-26 |
2023-08-13 |
Not clear |
| Dawn I Velligan, Cathy Carroll, Maureen J Lage, Kathleen Fairma. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Psychiatric services (Washington, D.C.). vol 66. issue 2. 2015-10-21. PMID:25321616. |
outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. |
2015-10-21 |
2023-08-13 |
Not clear |
| Dawn I Velligan, Cathy Carroll, Maureen J Lage, Kathleen Fairma. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Psychiatric services (Washington, D.C.). vol 66. issue 2. 2015-10-21. PMID:25321616. |
patients with treatment-resistant schizophrenia commonly receive nonrecommended drug regimens, including antipsychotic polypharmacy, sometimes in lieu of clozapine. |
2015-10-21 |
2023-08-13 |
Not clear |
| Marilena Gilca, Gabriela Piriu, Laura Gaman, Corina Delia, Liviu Iosif, Valeriu Atanasiu, Irina Stoia. A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. Psychopharmacology. vol 231. issue 24. 2015-10-13. PMID:24871701. |
the aims of this study were to investigate the antioxidative activity of paraoxonase and assess lipid profile as a cardiovascular risk factor in patients with schizophrenia under long-term clozapine or risperidone treatment. |
2015-10-13 |
2023-08-13 |
Not clear |
| Shi Hyun Kang, Hye Ree Han, Jong-il Lee, Rakesh Karmacharya, Hong Jin Jeon, Sungwon Ro. Effects of LEP, LEPR, ADIPOQ, MC4R and FTO polymorphisms on dyslipidemia in Korean patients with schizophrenia who are taking clozapine. Psychiatry research. vol 228. issue 1. 2015-10-08. PMID:25841316. |
effects of lep, lepr, adipoq, mc4r and fto polymorphisms on dyslipidemia in korean patients with schizophrenia who are taking clozapine. |
2015-10-08 |
2023-08-13 |
Not clear |
| G C Smith, H McEwen, J D Steinberg, P R Shepher. The activation of the Akt/PKB signalling pathway in the brains of clozapine-exposed rats is linked to hyperinsulinemia and not a direct drug effect. Psychopharmacology. vol 231. issue 23. 2015-10-07. PMID:24800899. |
the second generation antipsychotic drug clozapine is a much more effective therapy for schizophrenia than first generation compounds, but the reasons for this are poorly understood. |
2015-10-07 |
2023-08-13 |
rat |
| Adam Wysokiński, Iwona Kłoszewsk. Blood serum levels of CART peptide in patients with schizophrenia on clozapine monotherapy. Psychiatry research. vol 220. issue 1-2. 2015-10-07. PMID:25219614. |
blood serum levels of cart peptide in patients with schizophrenia on clozapine monotherapy. |
2015-10-07 |
2023-08-13 |
human |
| Adam Wysokiński, Iwona Kłoszewsk. Blood serum levels of CART peptide in patients with schizophrenia on clozapine monotherapy. Psychiatry research. vol 220. issue 1-2. 2015-10-07. PMID:25219614. |
we compared fasting serum cart levels in subjects with schizophrenia on clozapine monotherapy (n=24) with sex- and age-matched healthy controls (n=24). |
2015-10-07 |
2023-08-13 |
human |
| Antonio Bruno, Rocco A Zoccali, Elisabetta Abenavoli, Gianluca Pandolfo, Giuseppe Scimeca, Edoardo Spina, Maria Rosaria Anna Muscatell. Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study. Journal of clinical psychopharmacology. vol 34. issue 4. 2015-09-28. PMID:24911437. |
augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study. |
2015-09-28 |
2023-08-13 |
Not clear |
| Antonio Bruno, Rocco A Zoccali, Elisabetta Abenavoli, Gianluca Pandolfo, Giuseppe Scimeca, Edoardo Spina, Maria Rosaria Anna Muscatell. Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study. Journal of clinical psychopharmacology. vol 34. issue 4. 2015-09-28. PMID:24911437. |
the present 16-week open-label uncontrolled trial was aimed to explore the efficacy of adjunctive agomelatine on clinical symptoms and cognitive functioning in 20 schizophrenia patients showing partial response (brief psychiatric rating scale, mean [sd] baseline total score = 37.5 [6.6]) to clozapine monotherapy at the highest tolerated dosage. |
2015-09-28 |
2023-08-13 |
Not clear |
| Shani Pridan, Marnina Swartz, Yehuda Baruch, Shelly Tadger, Igor Plopski, Yoram Bara. Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. International psychogeriatrics. vol 27. issue 1. 2015-09-28. PMID:25166892. |
effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. |
2015-09-28 |
2023-08-13 |
Not clear |
| Shani Pridan, Marnina Swartz, Yehuda Baruch, Shelly Tadger, Igor Plopski, Yoram Bara. Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. International psychogeriatrics. vol 27. issue 1. 2015-09-28. PMID:25166892. |
we aimed to evaluate the effectiveness and safety of clozapine monotherapy in a diagnostically homogeneous group of elderly patients suffering from schizophrenia (dsm-iv-tr criteria). |
2015-09-28 |
2023-08-13 |
Not clear |
| Praveen Tripathi, Priyanka Goyal, Deepak Kumar, Om Prakas. High doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine. The Australian and New Zealand journal of psychiatry. vol 49. issue 2. 2015-09-28. PMID:25217184. |
high doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine. |
2015-09-28 |
2023-08-13 |
Not clear |
| Kazuaki Kawaura, Hiroyuki Koike, Kohnosuke Kinoshita, Daiji Kambe, Ayaka Kaku, Jun-ichi Karasawa, Shigeyuki Chaki, Hirohiko Hikich. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats. Behavioural brain research. vol 278. 2015-09-28. PMID:25300471. |
the increased immobility induced by mk-801 was attenuated by the atypical antipsychotic clozapine but not by either the typical antipsychotic haloperidol or the antidepressant imipramine, indicating that the increased immobility induced by subchronic treatment with mk-801 in the forced swimming test may represent a negative symptom of schizophrenia. |
2015-09-28 |
2023-08-13 |
rat |
| T Godoy, A Riva, J Ekströ. Salivary secretion effects of the antipsychotic drug olanzapine in an animal model. Oral diseases. vol 19. issue 2. 2015-09-23. PMID:22816733. |
olanzapine, introduced as an alternative to clozapine in schizophrenia therapy, is thought to display a receptor affinity similar to that of clozapine. |
2015-09-23 |
2023-08-12 |
Not clear |
| Giovana J Garcia, Marcos H Chagas, Carlos H Silva, João P Machado-de-Sousa, José A Crippa, Jaime E Halla. Structural and functional neuroimaging findings associated with the use of clozapine in schizophrenia: a systematic review. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 37. issue 1. 2015-09-22. PMID:25806554. |
structural and functional neuroimaging findings associated with the use of clozapine in schizophrenia: a systematic review. |
2015-09-22 |
2023-08-13 |
Not clear |
| Giovana J Garcia, Marcos H Chagas, Carlos H Silva, João P Machado-de-Sousa, José A Crippa, Jaime E Halla. Structural and functional neuroimaging findings associated with the use of clozapine in schizophrenia: a systematic review. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 37. issue 1. 2015-09-22. PMID:25806554. |
clozapine is an atypical antipsychotic with a specific profile of action indicated for treatment-resistant schizophrenia. |
2015-09-22 |
2023-08-13 |
Not clear |
| Vikram Oke, Frances Schmidt, Bikash Bhattarai, Md Basunia, Chidozie Agu, Amrit Kaur, Danilo Enriquez, Joseph Quist, Divya Salhan, Vijay Gayam, Prajakta Mungika. Unrecognized clozapine-related constipation leading to fatal intra-abdominal sepsis - a case report. International medical case reports journal. vol 8. 2015-09-22. PMID:26392790. |
clozapine is the preferred antipsychotic used for the treatment of resistant schizophrenia with suicidal ideation. |
2015-09-22 |
2023-08-13 |
Not clear |